Valuation — not yet established
No valuation for Antios Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($75.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Antios Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Nov 2021 | Early Stage VC (Series B1) | $75.0M | ▮ | ▮ |
| Jul 2020 | Seed Round | $4.4M | ▮ | ▮ |
| Nov 2018 | Early Stage VC | $15.0M | ▮ | ▮ |
How Antios Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Antios Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Antios Therapeutics raised?
- Antios Therapeutics has raised $75.0M in total funding across 3 recorded rounds.
- When did Antios Therapeutics last raise?
- Antios Therapeutics last raised in Nov 2021 (Early Stage VC (Series B1)), raising $75.0M.